Combination therapy failed to improve survival in both CD4−/− and CD8−/− tumor-bearing mice (Fig. 3d, e, respectively) indicating the enhanced antitumor response seen with the combination therapy is both CD4+ and CD8+ T cell-dependent. This evidence concerns the gene CD8A and neoplasm.